| 3.37 0.17 (5.31%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.17 | 1-year : | 4.43 |
| Resists | First : | 3.57 | Second : | 3.79 |
| Pivot price | 3.37  |
|||
| Supports | First : | 3.2 | Second : | 2.66 |
| MAs | MA(5) : | 3.29 |
MA(20) : | 3.43 |
| MA(100) : | 3.66 |
MA(250) : | 3.02 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 12.6 |
D(3) : | 12.2 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 5.32 | Low : | 1.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MDXH ] has closed above bottom band by 49.2%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 3.38 - 3.4 | 3.4 - 3.42 |
| Low: | 3.21 - 3.24 | 3.24 - 3.27 |
| Close: | 3.33 - 3.37 | 3.37 - 3.41 |
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Mon, 16 Mar 2026
Gene test flags prostate cancer patients who may avoid aggressive treatment - Stock Titan
Sat, 14 Mar 2026
MDxHealth SA (NASDAQ:MDXH) Short Interest Update - MarketBeat
Fri, 06 Mar 2026
Mdxhealth Earnings Call Highlights Fast Growth, Rising Costs - TipRanks
Wed, 04 Mar 2026
MDxHealth SA (MDXH.BR) Competitors - Meyka
Wed, 04 Mar 2026
BTIG reiterates MDxHealth stock rating on strong volume growth - Investing.com
Thu, 26 Feb 2026
MDxHealth (MDXH) Q4 2025 Earnings Call Transcript - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 5.136e+007 (%) |
| Held by Institutions | 3.602e+007 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.2e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -31.1 % |
| Operating Margin | -17.9 % |
| Return on Assets (ttm) | -6 % |
| Return on Equity (ttm) | -2 % |
| Qtrly Rev. Growth | 1.0788e+008 % |
| Gross Profit (p.s.) | 165967 |
| Sales Per Share | 257392 |
| EBITDA (p.s.) | -17655.6 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 8219.86 |
| Dividend | 22470 |
| Forward Dividend | 25720 |
| Dividend Yield | 666766% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|